Corbus Pharmaceuticals Holdings Inc (NASDAQ:CRBP) insider Barbara White acquired 4,638 shares of Corbus Pharmaceuticals stock in a transaction on Thursday, March 14th. The stock was acquired at an average price of $6.47 per share, with a total value of $30,007.86. Following the purchase, the insider now directly owns 184,159 shares in the company, valued at $1,191,508.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Shares of CRBP stock traded up $0.31 on Thursday, hitting $6.83. 2,275,625 shares of the stock were exchanged, compared to its average volume of 1,711,379. The company has a market capitalization of $385.87 million, a price-to-earnings ratio of -6.97 and a beta of 2.17. Corbus Pharmaceuticals Holdings Inc has a one year low of $4.50 and a one year high of $9.11.

Get Corbus Pharmaceuticals alerts:

Corbus Pharmaceuticals (NASDAQ:CRBP) last posted its quarterly earnings results on Tuesday, March 12th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.07). The firm had revenue of $1.93 million for the quarter, compared to the consensus estimate of $1.99 million. Corbus Pharmaceuticals had a negative return on equity of 101.91% and a negative net margin of 1,154.52%. On average, analysts predict that Corbus Pharmaceuticals Holdings Inc will post -0.91 EPS for the current fiscal year.

A number of research analysts have issued reports on the company. BidaskClub upgraded Corbus Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, December 27th. HC Wainwright assumed coverage on Corbus Pharmaceuticals in a research note on Wednesday, December 26th. They issued a “buy” rating and a $24.00 price objective for the company. Cantor Fitzgerald restated a “buy” rating and issued a $38.00 price objective on shares of Corbus Pharmaceuticals in a research note on Tuesday. ValuEngine upgraded Corbus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 31st. Finally, Zacks Investment Research downgraded Corbus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $26.75.

Hedge funds have recently bought and sold shares of the company. Barclays PLC grew its stake in shares of Corbus Pharmaceuticals by 5,967.8% during the 4th quarter. Barclays PLC now owns 9,041 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 8,892 shares during the period. Metropolitan Life Insurance Co. NY grew its stake in shares of Corbus Pharmaceuticals by 357.7% during the 4th quarter. Metropolitan Life Insurance Co. NY now owns 16,973 shares of the biopharmaceutical company’s stock worth $99,000 after acquiring an additional 13,265 shares during the period. D.A. Davidson & CO. bought a new position in shares of Corbus Pharmaceuticals during the 3rd quarter worth $156,000. Bank of America Corp DE lifted its holdings in Corbus Pharmaceuticals by 6.7% during the 4th quarter. Bank of America Corp DE now owns 37,304 shares of the biopharmaceutical company’s stock worth $218,000 after purchasing an additional 2,335 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. lifted its holdings in Corbus Pharmaceuticals by 52.7% during the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 35,884 shares of the biopharmaceutical company’s stock worth $271,000 after purchasing an additional 12,380 shares in the last quarter. Institutional investors own 45.31% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: “Corbus Pharmaceuticals Holdings Inc (CRBP) Insider Barbara White Acquires 4,638 Shares” was first published by Dakota Financial News and is owned by of Dakota Financial News. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright & trademark legislation. The original version of this news story can be viewed at https://dakotafinancialnews.com/2019/03/14/corbus-pharmaceuticals-holdings-inc-crbp-insider-barbara-white-acquires-4638-shares.html.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid-mimetic drug to resolve chronic inflammation and fibrotic processes in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus diseases.